JARISLOWSKY FRASER Ltd Sells 56,630 Shares of Boston Scientific Co. (NYSE:BSX)

JARISLOWSKY FRASER Ltd lessened its stake in shares of Boston Scientific Co. (NYSE:BSXFree Report) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,028,215 shares of the medical equipment provider’s stock after selling 56,630 shares during the period. JARISLOWSKY FRASER Ltd’s holdings in Boston Scientific were worth $175,061,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in BSX. Bruce G. Allen Investments LLC bought a new position in shares of Boston Scientific in the 4th quarter valued at about $28,000. Sachetta LLC bought a new position in shares of Boston Scientific in the 4th quarter valued at about $32,000. Frazier Financial Advisors LLC bought a new position in shares of Boston Scientific in the 4th quarter valued at about $32,000. Motco lifted its holdings in shares of Boston Scientific by 136.3% in the 3rd quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 372 shares during the last quarter. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Boston Scientific by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 215 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $66.35, for a total value of $463,322.05. Following the completion of the sale, the executive vice president now directly owns 53,788 shares in the company, valued at $3,568,833.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Edward J. Ludwig sold 9,818 shares of Boston Scientific stock in a transaction on Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now directly owns 41,374 shares in the company, valued at $3,032,300.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Friday, March 1st. The stock was sold at an average price of $66.35, for a total transaction of $463,322.05. Following the sale, the executive vice president now owns 53,788 shares of the company’s stock, valued at $3,568,833.80. The disclosure for this sale can be found here. Insiders sold a total of 67,616 shares of company stock worth $4,819,057 over the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 1.7 %

BSX traded up $1.25 during trading on Monday, hitting $75.63. The stock had a trading volume of 4,786,600 shares, compared to its average volume of 6,487,011. The company has a market capitalization of $110.96 billion, a PE ratio of 63.55, a PEG ratio of 2.60 and a beta of 0.77. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $76.25. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The stock has a 50 day simple moving average of $70.61 and a two-hundred day simple moving average of $63.86.

Boston Scientific (NYSE:BSXGet Free Report) last announced its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.05. The company had revenue of $3.86 billion during the quarter, compared to the consensus estimate of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. On average, research analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Barclays increased their price target on shares of Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research report on Thursday, April 25th. Evercore ISI increased their price objective on shares of Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Citigroup increased their price objective on shares of Boston Scientific from $85.00 to $87.00 and gave the stock a “buy” rating in a research report on Wednesday, May 22nd. Finally, Mizuho increased their price objective on shares of Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $75.41.

View Our Latest Stock Report on Boston Scientific

About Boston Scientific

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.